Liver Cancer - Nexavar (sorafenib) Significantly Extends Overall Survival By 44% In A

New cases in Pous 2064, HIV = 175, AIDS = 26, Death = 2. HIV rate is very high in Housewives than sex workers in Nepal ! ! ! HIV status in Nepal till 2005: Total Adult=70000, Adult Prevalence (15-49)=0.55%, Number of Women (15-49) LWHA=15,310 (22%), HIV Prevalence rate in IDUs=32.7%, HIV prevalence rate in sex worker=3.8%, HIV prevalence rate in client of SW=2.1%. The latest U.N. report shows that 65 million people have been infected with HIV since it was first identified 25 years ago. Twenty five million people have died of AIDS.

Welcome to the xenoMED, an online Medical Community where Academically sound, Professionally conscious and Socially responsible Medical Students, Doctors & Health Professionals interact with each other globally.

Medicine is the only profession that incessantly tries to destroy its own existence. Howsoever you may be associated with basic and/or clinical medicine - student or professor, physician or surgeon, undergraduate or postgraduate - this is your place to share your knowledge, and learn more. Just get the message across!

You are currently viewing our communiy as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, Join Our Medical Cummunity Today!

If you have any problems with the registration process or your account login, please contact us.

		xenoMED > News Room > Health News > Medical News Today
Liver Cancer - Nexavar (sorafenib) Significantly Extends Overall Survival By 44% In A

LinkBack

Thread Tools

Display Modes

(#1 (permalink))

Angel is Offline

xenoMED

Posts: 76,099

Images: 316

Blog Entries: 16

Thanks: 93

Thanked 26,736 Times in 26,617 Posts

Join Date: Oct 2005

Liver Cancer - Nexavar (sorafenib) Significantly Extends Overall Survival By 44% In A - 05-06-2007, 04:25 AM

Data presented today at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO) has shown that Nexavar (sorafenib) tablets significantly extended overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44% (HR=0.69; p-value=0.0006). [click link for full article]

More...

Angel
xenoMED | NDR
“Nothing brings me more happiness than helping people in the society. It is a goal and an essential part of my life - a kind of destiny.”

The Following User Says Thank You to Angel For This Useful Post:
RonSijm (19-08-2008)

Remove advertisements

Sponsored links

« Clinical Data Suggest Potential Versatility Of ALIMTA-Based Regimens In Lung Cancer | Presidential Candidates Should Focus On Emergency Departments, Elder Care Before They »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts vB code is On Smilies are On [IMG] code is On HTML code is Off Trackbacks are On Pingbacks are On Refbacks are On

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
546 QA Biochemistry Test	Oak	Step I	1	29-10-2007 11:23 PM
Liver Cancer - Nexavar (sorafenib) Significantly Extends Overall Survival By 44% In A	Angel	Medical News Today	0	05-06-2007 01:26 AM
ASCO: Sorafenib (Nexavar) Improves Survival in Primary Liver Cancer	Angel	MedPage Today	0	04-06-2007 06:21 PM
Can Most Types Of Cancers Be Prevented?	Angel	Medical Breakthrough	1	21-12-2005 07:26 PM

Remove advertisements

Hosted and Maintained by: